aTyr Pharma (ATYR) vs Kyntra Bio (KYNB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kyntra Bio (KYNB) has outperformed aTyr Pharma (ATYR) over the past year, losing 47.7% versus a loss of 74.5%. Over five years, ATYR leads with a -97.1% price change compared with -97.8% for KYNB. Kyntra Bio is the larger company by market cap ($24.9 million vs $24.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATYR | KYNB |
|---|---|---|
| Share price | $0.2529 | $6.15 |
| Market cap | $24.81M | $24.90M |
| 1-day change | -0.94% | +3.19% |
| YTD return | -67.39% | -32.12% |
| 1-year return | -74.47% | -47.72% |
| 5-year return | -97.07% | -97.84% |
| EPS (TTM) | $-0.62 | $-7.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.12 | $11.65 |
| 52-week low | $0.25 | $5.62 |
| Distance from 52-week high | -77.42% | -47.21% |
| Analyst consensus | buy | none |
| Avg. price target upside | +1030.88% | +545.04% |
| Average volume | 3.24M | 18.29K |
| Shares outstanding | 98.09M | 4.05M |
| Employees | 58 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KYNB has outperformed ATYR by 26.8 percentage points over the past year.
About aTyr Pharma
ATYR stock →aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 58 employees
About Kyntra Bio
KYNB stock →Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
ATYR vs KYNB FAQ
Which is bigger, aTyr Pharma or Kyntra Bio?
Kyntra Bio (KYNB) is larger, with a market capitalization of $24.90M compared with $24.81M for aTyr Pharma (ATYR).
Which stock has performed better over the past year, ATYR or KYNB?
KYNB returned -47.72% over the past 12 months, compared with -74.47% for ATYR (price return, excluding dividends). Past performance does not predict future results.
Are aTyr Pharma and Kyntra Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for aTyr Pharma and Biotechnology: Pharmaceutical Preparations for Kyntra Bio.